文献知网节
  • 记笔记
摘要:The deubiquitinating enzyme,ubiquitin-specific protease7(USP7),plays a pivotal role in regulating the cellular processes.The aberrant USP7 has been implicated in the occurrence of cancer,including human prostate cancer,multiple myeloma and chronic lymphocytic leukemia[1].Besides the expression level of the USP7 was also directly associated with the tumor aggressiveness and predicted the poor prognosis.In particularly,USP7 has been reported regulation of p53-pathway[2].Thus,USP7 has attracted increasing attention as a validated oncology target for cancer therapy within the decades.Although several USP7 inhibitors had been reported(Fig.1),there are no clinical candidates so far[3].Given the importance of USP7 which acts on the oncogene and the urgent to discovery the novel USP7 inhibitors,modulation of USP7 activity has the potential to offer therapeutic benefit for the treatment of cancer.
会议名称:

第11届世界华人药物化学研讨会(ISCMC 2018)

会议时间:

2018-08-24

会议地点:

中国河南郑州

  • 专辑:

    医药卫生

  • 专题:

    药学

  • 分类号:

    R91

  • 手机阅读
    即刻使用手机阅读
    第一步

    扫描二维码下载

    "移动知网-全球学术快报"客户端

    第二步

    打开“全球学术快报”

    点击首页左上角的扫描图标

    第三步

    扫描二维码

    手机同步阅读本篇文献

  • CAJ下载
  • PDF下载

下载手机APP用APP扫此码同步阅读该篇文章

下载:21 页码:271 页数:1 大小:42k

相关推荐
  • 相似文献
  • 读者推荐
  • 相关基金文献
  • 关联作者
  • 相关视频